NeuroMetrix (NASDAQ:NURO) Research Coverage Started at StockNews.com

StockNews.com initiated coverage on shares of NeuroMetrix (NASDAQ:NURO) in a research note issued to investors on Saturday. The firm issued a sell rating on the medical device company’s stock.

NeuroMetrix Trading Up 0.3 %

NURO stock opened at $4.38 on Friday. The company has a market cap of $8.94 million, a price-to-earnings ratio of -0.96 and a beta of 2.18. The firm has a 50 day moving average of $4.06 and a 200-day moving average of $3.93. NeuroMetrix has a 12-month low of $2.66 and a 12-month high of $4.73.

About NeuroMetrix

NeuroMetrix, Inc, a commercial stage neurotechnology company, engages in designing, building, and marketing medical devices that stimulate and analyze nerve response for diagnostic and therapeutic purposes in the United States, Europe, Japan, and China. Its marketed products include DPNCheck, a nerve conduction test that is used to evaluate peripheral neuropathies, such as diabetic peripheral neuropathy; Quell, a wearable device for symptomatic relief and management of chronic pain; and ADVANCE system offers services to device and provide disposable electrodes to a customer base of hand surgeons and manufacturers for industrial health use.